JP2015524055A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524055A5
JP2015524055A5 JP2015513339A JP2015513339A JP2015524055A5 JP 2015524055 A5 JP2015524055 A5 JP 2015524055A5 JP 2015513339 A JP2015513339 A JP 2015513339A JP 2015513339 A JP2015513339 A JP 2015513339A JP 2015524055 A5 JP2015524055 A5 JP 2015524055A5
Authority
JP
Japan
Prior art keywords
mmp2
cancer
levels
treatment
angiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015513339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524055A (ja
Filing date
Publication date
Priority claimed from EP12305565.9A external-priority patent/EP2667193A1/en
Application filed filed Critical
Publication of JP2015524055A publication Critical patent/JP2015524055A/ja
Publication of JP2015524055A5 publication Critical patent/JP2015524055A5/ja
Withdrawn legal-status Critical Current

Links

JP2015513339A 2012-05-23 2013-05-23 ガン患者における抗血管新生療法に対する応答及び該療法後の生存についての予知バイオマーカーとしてのｍｍｐ２ Withdrawn JP2015524055A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305565.9 2012-05-23
EP12305565.9A EP2667193A1 (en) 2012-05-23 2012-05-23 MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
PCT/IB2013/054275 WO2013175429A1 (en) 2012-05-23 2013-05-23 Mmp2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients

Publications (2)

Publication Number Publication Date
JP2015524055A JP2015524055A (ja) 2015-08-20
JP2015524055A5 true JP2015524055A5 (enExample) 2016-06-16

Family

ID=48782563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513339A Withdrawn JP2015524055A (ja) 2012-05-23 2013-05-23 ガン患者における抗血管新生療法に対する応答及び該療法後の生存についての予知バイオマーカーとしてのｍｍｐ２

Country Status (4)

Country Link
US (1) US20150148248A1 (enExample)
EP (2) EP2667193A1 (enExample)
JP (1) JP2015524055A (enExample)
WO (1) WO2013175429A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025926B1 (ru) 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
AU2013353839A1 (en) 2012-12-03 2015-06-18 Almac Diagnostics Limited Molecular diagnostic test for cancer
GB201409476D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular subtype for use in prognosis
ES2908848T3 (es) * 2016-01-25 2022-05-04 Sanofi Sa Método de predicción del resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer midiendo el nivel de un biomarcador de plasma
CN107604074B (zh) * 2017-10-27 2020-06-30 中南大学湘雅医院 胶质瘤预后标志物circ15:101235082|101235577及应用
CN107937532B (zh) * 2017-12-28 2020-06-30 中南大学湘雅医院 胶质瘤诊断标志物hsa_circ_0021827及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EA025926B1 (ru) * 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак

Similar Documents

Publication Publication Date Title
Wadhwa et al. Gastric cancer—molecular and clinical dimensions
Quinn et al. Extracellular RNAs: development as biomarkers of human disease
Hoseok et al. Lung cancer biomarkers
Wehland et al. Biomarkers for anti-angiogenic therapy in cancer
Xu et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1α, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer
Shlyankevich et al. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities
JP2015524055A5 (enExample)
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
Zhang et al. Increased expression of miR-222 is associated with poor prognosis in bladder cancer
Tabor et al. How to predict metastasis in luminal breast cancer? Current solutions and future prospects
JP2016500110A5 (enExample)
JP2010538609A5 (enExample)
RU2011106957A (ru) Онкоген nrf2 и его применение
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
Davey et al. Evaluating the role of circulating microRNAs to aid therapeutic decision making for neoadjuvant chemotherapy in breast cancer: a prospective, multicenter clinical trial
Nguyen et al. A panel of TMPRSS2: ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity
Yi et al. High expression of peroxiredoxin 4 affects the survival time of colorectal cancer patients, but is not an independent unfavorable prognostic factor
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
JP2016536568A5 (enExample)
Wei et al. Proteome differences between hepatitis B virus genotype-B-and genotype-C-induced hepatocellular carcinoma revealed by iTRAQ-based quantitative proteomics
Chen et al. CDH2 expression is of prognostic significance in glioma and predicts the efficacy of temozolomide therapy in patients with glioblastoma
Ma et al. Combined overexpression of cadherin 6, cadherin 11 and cluster of differentiation 44 is associated with lymph node metastasis and poor prognosis in oral squamous cell carcinoma
Peng et al. Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features
Mei et al. MicroRNAs for diagnosis and treatment of colorectal cancer
Liu et al. The impact of high co-expression of Sp1 and HIF1α on prognosis of patients with hepatocellular cancer